Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Stomach cancer is the most common malignant disease and the second most common cause of
cancer-related deaths in the Korea. The elderly are primarily affected by the disease with
most gastric cancer-related deaths occuring in patients aged 65 years or older. Systemic
chemotherapy improves the quantity and quality of life in patients with gastric cancer when
compared with best supportive care. However, elderly cancer patients often present with
concomitant co-morbidities and age-associated physiologic problems that make the selection of
optimal treatment difficult. There is also uncertainty about the use of systemic palliative
chemotherapy in elderly patients because of under representation of this age group in
clinical trials. Therefore, this phase II trial was planned to investigate efficacy and
toxicities of combination chemotherapy with attenuated dose of S-1 and oxaliplatin
(attenuated SOX)in patients with elderly AGC